

Estrogen Receptor Binding Site Associated Antigen 9 Recombinant Protein | EBAG9 recombinant protein

Recombinant Human Estrogen Receptor Binding Site Associated Antigen 9

CATALOG # AAA38729	HOST E Coli
------------------------------	-----------------------

PRODUCT SYNONYMS

Estrogen Receptor Binding Site Associated Antigen 9; Recombinant Human Estrogen Receptor Binding Site Associated Antigen 9; EBAG9 Human; Estrogen Receptor Binding Site Associated Antigen 9 Human Recombinant; EB9; PDAF; RCAS1; EBAG9; Receptor-binding cancer antigen expressed on SiSo cells; Cancer-associated surface antigen RCAS1; Estrogen receptor-binding fragment-associated gene 9 protein; EBAG9 recombinant protein

PRODUCT SPECIFICATIONS

Host	E Coli
Purity/Purification	Greater than 90% as determined by SDS-PAGE.
Form/Format	The EBAG9 protein solution contains 20mM Tris-HCl pH-8, 1mM DTT, 2mM EDTA and 10% glycerol. Sterile Filtered colorless solution.
Sequence	MGSSHHH HHHSSGLVPR GSHMRS GRGRKLSGDQ ITLPTTVDYS SVPKQTDVEE WTSWDEDAPT SVKIEGGNGN VATQONSLEQ LEPDYFKDMT PTIRKTQKIV IKKREPLNFG IPDGSTGFSS RLAATQDLPF IHQSSELGDL DTWQENTNAW EEEEDAAWQA EEVLRQQKLA DREKRAAEQQ RKKMEKEAQR LMKKEQNKIG VKLS
Sequence Length	213

ADDITIONAL INFORMATION

Related Product Information for EBAG9 recombinant protein	Description: EBAG9 Human Recombinant produced in E Coli is a single, non-glycosylated polypeptide chain containing 207 amino acids (28-213) and having a molecular mass of 23.4 kDa. The EBAG9 protein is fused to a 20 amino acid His-Tag at N-terminus and purified by standard chromatography techniques. Introduction: EBAG9 is a type III transmembrane protein that is primarily located in the Golgi. EBAG9 is a tumor-associated antigen that is expressed at high frequency in a variety of cancers, such as advanced breast and prostate cancers. while the EBAG9 acts to inhibit the growth of receptor-binding cells and induced apoptosis of immune cells, cancer cells may evade immune surveillance. Thus immunodetection of EBAG9 expression can be a negative prognostic indicator. EBAG9 promotes progression of bladder cancer. In rheumatoid arthritis, the deficiency of EBAG9 induces CTL infiltration through failure to evade immune attack, therefore leading to apoptosis of the synovial lining cells. EBAG9 is involved in controlling exocytosis processes. EBAG9 expression plays a role in the progression of oral squamous cell carcinoma. EBAG9 plays a specific role in premature stages of breast carcinogenesis.
Product Categories/Family for EBAG9 recombinant protein	Recombinant & Natural Proteins ; Recombinant Proteins

NCBI AND UNIPROT INFORMATION

NCBI GI #	525459422
NCBI GeneID	9166
NCBI Accession #	NP_001265867.1
NCBI GenBank Nucleotide #	NM_001278938.1

UniProt Accession #	O00559 ; Q5Y8C7 ; Q6IB20 ; Q9BS76 ; A8K3N6
Molecular Weight	29,466 Da
NCBI Official Full Name	receptor-binding cancer antigen expressed on SiSo cells
NCBI Official Synonym Full Names	estrogen receptor binding site associated, antigen, 9
NCBI Official Symbol	EBAG9
NCBI Official Synonym Symbols	EB9; PDAF
NCBI Protein Information	receptor-binding cancer antigen expressed on SiSo cells; cancer-associated surface antigen RCAS1; estrogen receptor-binding fragment-associated gene 9 protein
UniProt Protein Name	Receptor-binding cancer antigen expressed on SiSo cells
UniProt Gene Name	EBAG9
UniProt Synonym Gene Names	RCAS1
UniProt Entry Name	RCAS1_HUMAN

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://stage.aaabiotech.com/ebag9-recombinant-protein-e-coli/38729>